Clinical outcomes and emergence of resistance of Pseudomonas aeruginosa infections treated with ceftolozane-tazobactam versus ceftazidime-avibactam | Synapse
September 4, 2024
Clinical outcomes and emergence of resistance of Pseudomonas aeruginosa infections treated with ceftolozane-tazobactam versus ceftazidime-avibactam
Key Points
Key points are not available for this paper at this time.
Abstract
Few studies compare outcomes of patients with difficult-to-treat resistance (DTR)